Definium Therapeutics (DFTX) Accounts Payables (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Accounts Payables data on file, last reported at $7.1 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $7.1 million, up 214.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 million (up 214.24% YoY), and the FY2025 annual result was $5.3 million, up 166.02% from the prior year.
• Accounts Payables advanced to $7.1 million in Q1 2026 per DFTX's latest filing, from $5.3 million in the prior quarter.
• Over five years, Accounts Payables peaked at $8.6 million in Q2 2023 and troughed at $732000.0 in Q2 2022.
• A 5-year average of $4.2 million and a median of $3.3 million in 2022 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 1071.72% in 2023, then plunged 72.04% in 2024.
• A 5-year view of Accounts Payables shows it stood at $2.1 million in 2022, then soared by 95.93% to $4.1 million in 2023, then plunged by 51.4% to $2.0 million in 2024, then soared by 166.02% to $5.3 million in 2025, then jumped by 33.29% to $7.1 million in 2026.
• Business Quant data shows DFTX's Accounts Payables at $7.1 million in Q1 2026, $5.3 million in Q4 2025, and $8.1 million in Q3 2025.